Develops small molecule-based therapeutics for human health applications.
Dec 2025Revenue $3.85M/yrExpenses $17.9M/yr
No trendCash runway ≈ 11 months from Dec 2025
Figures by year
When will Evogene be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2025, revenue was $3.85M and expenses $17.9M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $3.85M | $17.9M | −$14.0M |
| Dec 2024 | $5.58M | $24.4M | −$18.8M |
| Dec 2023 | $2.98M | $25.2M | −$22.2M |
| Dec 2022 | $1.68M | $28.6M | −$26.9M |
| Dec 2021 | $930K | $31.9M | −$31.0M |
| Dec 2020 | $1.04M | $25.9M | −$24.8M |
| Dec 2019 | $753K | $21.9M | −$21.2M |
| Dec 2018 | $1.75M | $21.7M | −$20.0M |
| Dec 2017 | $3.38M | $25.3M | −$21.9M |
| Dec 2016 | $6.54M | $27.6M | −$21.1M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.